Bliss GVS Pharma (506197) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with unmodified opinions from statutory auditors.

• Final dividend of ₹1 per equity share recommended for FY 2025-26, subject to shareholder approval.

• Board approved re-appointment of BDO India Services as internal auditor for FY 2026-27.

• 41st AGM scheduled for July 15, 2026, via video conferencing.

Financial highlights

• Standalone revenue for FY 2025-26 was ₹72,980.76 lakh, up from ₹55,720.46 lakh year-over-year.

• Standalone net profit for FY 2025-26 was ₹9,687.44 lakh, compared to ₹6,896.87 lakh last year.

• Consolidated revenue for FY 2025-26 was ₹92,711.28 lakh, up from ₹80,972.62 lakh year-over-year.

• Consolidated net profit for FY 2025-26 was ₹13,472.77 lakh, compared to ₹9,025.53 lakh last year.

• Earnings per share (EPS) for FY 2025-26 stood at ₹12.23 (consolidated) and ₹9.17 (standalone).

Outlook and guidance

• No explicit forward-looking guidance provided, but dividend recommendation and AGM scheduling indicate confidence in ongoing operations.